Report Summary: (2019-2026)
Data Bridge Market research presents the Top quality and comprehensive HEPATOCELLULAR CARCINOMA DRUGS research report which provides clear insights into market dynamics and prospects the whole market including global production, revenue forecast, value and volume. This report deeply study competitive scenario and evaluated the crucial vendors with regard to product stratification and business strategies.
Market Segment by Companies, this report covers Exelixis, Inc., Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, SillaJen, Inc., Bayer AG, Janssen Global Services, LLC, Pfizer Inc., CELGENE CORPORATION, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline plc., Transgene, others
Click More Info| Get Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hepatocellular-carcinoma-drugs-market
Description
Global hepatocellular carcinoma drugs market is rising gradually with the steady CAGR of 3.9% in the forecast period of 2020-2027. The report consists of base year 2019 and historic year 2018. Ongoing strong pipeline for hepatocellular carcinoma by several companies will bring a great opportunity for the market growth.
Hepatocellular carcinoma (HCC) is the most common type of primary malignancy in liver. The major causes of this type of liver cancer are chronic liver diseases including cirrhosis caused by hepatitis B and hepatitis C. The prevalence of HCC has evolved significantly over the past few decades and it has become the third leading cause of deaths by cancer worldwide. Due to high prevalence of hepatitis B and hepatitis C chronic liver diseases are increasing, the incidence of HCC is more in Asia and Africa, as compared to Africa and Asia, the incidence of HCC is highest in Asia, with incidence rates in men of 35 per 100,000 populations.
Segmentation of the market
- By Therapy Type (Targeted Therapy, Immunotherapy, Others),
- Treatment Type (Medication, Surgery, Radiotherapy, Chemotherapy, Others),
- Route of Administration (Oral, Injectable, Others),
- End- Users (Hospitals, Homecare, Specialty Clinics, Others),
- Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others)
Geographical landscape covered in the report
This HEPATOCELLULAR CARCINOMA DRUGS report covers a geographical landscape including the region like North America, South America, Asia and Pacific region, Middle East and Africa and Europe. Other vital key regions are also taken into account while developing this report.
For Early Buyers | Get Up to 30% Discount on This Report: https://databridgemarketresearch.com/request-a-discount/global-hepatocellular-carcinoma-drugs-market
Questions related to the report:
- What does this HEPATOCELLULAR CARCINOMA DRUGS market research report offers?
This HEPATOCELLULAR CARCINOMA DRUGS report helps you to find about the key industry trends, threats and opportunities. It informs your decision for marketing strategy and planning. The most important its HEPATOCELLULAR CARCINOMA DRUGS report helps you to quickly build competitive intelligence in this rapidly changing market.
- Which techniques are utilized to overcome the threats?
Before creating this HEPATOCELLULAR CARCINOMA DRUGS report different type of tools and techniques such as SWOT analysis, Porter’s five analysis, Pestle Analysis, Industry chain analysis are utilized which helps the readers to overcome the threats of the market.
Competitive Analysis of the market
The HEPATOCELLULAR CARCINOMA DRUGS report tracks the key competitors in the market along with the company profiles which provide market position and basic information of the key competitors. Revenue figure, growth rate and gross margin is also included in the report.
Market Drivers and Restraints
- Advancement in technology, personalized medicine and cost effective treatment procedures are key factors responsible for growth of the market
- Pharmaceutical companies are investing a good fortune in the research and development of anticancer drugs; which will propel the market in the forecast period
- Growing incidence of liver cancer due to increasing geriatric population and unorganized lifestyle is also escalate the market in the near future
- Strict regulatory policies for approval of novel drugs hinders the growth of the market
- Drug trail failures in the pipeline is also hampering the market in the forecast period
Key Developments in the Market:
In January 2019, Exelixis, Inc. received the U.S. FDA approval for Cabometyx (cabozantinib) for the treatment of patients with hepatocellular carcinoma (HCC) pre-treated with sorafenib. Cabozantinib is the new treatment option for HCC with significant efficacy and safety profile. This new therapy will provide better treatment for the patients and will expands the business of the company
In November 2018, Merck & Co., Inc. received an accelerated approval for Keytruda (pembrolizumab) from the U.S. FDA for the treatment of patients with HCC who have been previously treated with sorafenib. The agent is also used in combination with carboplatin and either paclitaxel or nab-paclitaxel for first-line treatment of lung cancer. This approval will help the company to gain the marketing exclusivity of the drug product for its marketing and commercialization
Major Points Covered in Table of Contents:
- Global Hepatocellular Carcinoma Drugs Platforms Market Overview
- Economic Impact on Industry
- Market Competition by Manufacturers
- Production, Revenue (Value) by Region
- Supply (Production), Consumption, Export, Import by Regions
- Production, Revenue (Value), Price Trend by Type
- Global Hepatocellular Carcinoma Drugs Platforms Market Analysis by Application
- Manufacturing Cost Analysis
- Industrial Chain, Sourcing Strategy and Downstream Buyers
- Marketing Strategy Analysis, Distributors/Traders
- Market Effect Factors Analysis
- Global Hepatocellular Carcinoma Drugs Platforms Market Forecast
Read Complete Details with TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-hepatocellular-carcinoma-drugs-market
Conclusion:
This HEPATOCELLULAR CARCINOMA DRUGS research report gives the outcome that matters most to the client. The research carried out in this report suggests what is going to be beneficial and how the report will help the business to grow.
